6 results about "Shigella sonnei" patented technology

The invention relates to application of a scavenger receptor A antibody in preparation of a medicine for inhibiting plasmodium transmission, and belongs to the technical field of malaria prevention and treatment. Aiming at the technical problem that in the prior art, the drug resistance of plasmodium to drugs and the resistance of mosquito vector to insecticides are increasingly serious, so that the malaria propagation control effect is reduced, the invention provides a scavenger receptor A antibody which is specifically combined with a scavenger receptor A on the surface of macrophage to inhibit the phagocytic function of the scavenger receptor A, so that the control effect of malaria propagation is improved. Therefore, the proliferation of antimalarial active bacteria (such as Elizabeth, shigella sonnei or klebsiella oxytoca) in the stomach of the anopheles is promoted, and the development of plasmodium in the midgut of the anopheles is indirectly blocked. The antibody can be used alone or in combination with a Pfs25 antibody. The anopheles infection rate and the number of oocysts are remarkably reduced (for example, the infection rate is reduced from 81.7% to 6%), an eco-friendly biological control mode which is not prone to drug resistance is provided, and a new strategy is provided for malaria transmission blocking.

The invention discloses a group of antibacterial polypeptides aiming at gram-negative bacteria, and belongs to the technical field of biological medicines. According to the invention, a group of antibacterial peptides is obtained through screening, and the antibacterial peptides have good broad-spectrum antibacterial performance on escherichia coli, salmonella typhimurium, pseudomonas aeruginosa, klebsiella pneumoniae, shigella sonnei and stenotrophomonas maltophilia. Wherein the hemolytic activity and toxicity of the antibacterial peptides 11A-1, 11A-4 and 11A-5 are lower than therapeutic concentration threshold values, and the antibacterial peptides 11A-1, 11A-4 and 11A-5 can be used for preparing drugs or medical products for treating multi-drug-resistant bacterial infection.

This invention provides a highly lytic Shigella phage and its applications, belonging to the field of bioengineering technology. The phage is named vB-SsoS-Q1, classified as Shigella sonnei phage, and deposited at the China General Microbiological Culture Collection Center (CGMCC) with accession number CGMCC No. 45414. This phage is a double-stranded DNA phage with an icosahedral head approximately 75 nm long and 70 nm wide, possessing a retractable tail. It belongs to the class Tailed Phages, with a full-length gene of 50326 bp. It does not contain virulence or drug resistance genes, exhibits highly efficient lytic ability, and can lyse broadly against Shigella and Escherichia coli. This phage can be applied to prevent and treat bacterial diarrhea in livestock and poultry, for the biopreservation of fresh meat, dairy products, and other foods, effectively controlling contamination by multidrug-resistant Shigella, and providing a safe and efficient new solution to replace antibiotics.

The invention belongs to the field of gene detection, and particularly relates to a characteristic gene combination for predicting antibiotic susceptibility phenotype of shigella sonnei, a kit and application of the characteristic gene combination. The drug sensitive phenotype of shigella sonnei to antibiotics is judged by detecting specific genes or mutation, the method has the advantages of high accuracy, high sensitivity and high specificity, and accurate diagnosis and treatment of infection are facilitated.

The present invention, in embodiments, relates to a multivalent vaccine comprising a combination of two or more different monovalent Shigella oligosaccharide protein conjugates and an adjuvant. One of the vaccine components can be a Shigella sonnei oligosaccharide- protein conjugate and the other three can be Shigella flexneri oligosaccharide-protein conjugates, specifically, S. flexneri 2a, S. flexneri 3a and S. flexneri 6, respectively. All conjugates feature sOS components acting as surrogates of the heterogeneous Shigella surface polysaccharide antigens characteristic of each one of the selected Shigella serotypes. The multivalent vaccine of the present invention is made for the prevention and / or treatment of disease caused by Shigella, in particular S. sonnei and S. flexneri.

The invention is concerning a medical preparation comprising bicyclic heptapeptides for use in vertebrates or humans suffering from an infection caused by Gram-negative bacteria like Pseudomonas aeruginosa, Klebsiella pneumoniae, Acineto-bacter baumannii, Neisseria gonorrhoeae, Chlamydia trachomatis, Shigella sonnei, Salmonella enterica Typhimurium LT2, Enterobacter spp., Bifidobacterium longum, Bacteroides fragilis, Lactobacillus reuteri, Enterococcus spp., Yersinia pestis and numerous other Gram-negative bacteria.